These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9717065)

  • 1. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study.
    Goldbourt U; Brunner D; Behar S; Reicher-Reiss H
    Eur Heart J; 1998 Jul; 19 Suppl H():H42-7. PubMed ID: 9717065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress.
    Ericsson CG
    Eur Heart J; 1998 Jul; 19 Suppl H():H37-41. PubMed ID: 9717064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study.
    Arcavi L; Behar S; Caspi A; Reshef N; Boyko V; Knobler H
    Am Heart J; 2004 Feb; 147(2):239-45. PubMed ID: 14760320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial.
    Goldenberg I; Boyko V; Tennenbaum A; Tanne D; Behar S; Guetta V
    Arch Intern Med; 2009 Mar; 169(5):508-14. PubMed ID: 19273782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome.
    Tenenbaum A; Motro M; Fisman EZ; Tanne D; Boyko V; Behar S
    Arch Intern Med; 2005 May; 165(10):1154-60. PubMed ID: 15911729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial).
    Goldenberg I; Goldbourt U; Boyko V; Behar S; Reicher-Reiss H;
    Am J Cardiol; 2006 Feb; 97(4):466-71. PubMed ID: 16461038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design features of a five-year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
    de Faire U; Ericsson CG; Hamsten A; Nilsson J
    Drugs Exp Clin Res; 1995; 21(3):105-24. PubMed ID: 7555614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of bezafibrate on HDL2/HDL3 ratio in postmenopausal hypertriglyceridemic women.
    Ushiroyama T; Sakuma K; Nosaka S
    J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):142-8. PubMed ID: 16891292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fibrates in the secondary prevention of ischemic cardiopathy].
    Posadas Romero C
    Arch Cardiol Mex; 2001; 71 Suppl 1():S139-41. PubMed ID: 11565320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety and tolerability of lovastatin and bezafibrate retard in patients with hypercholesterolemia.
    Schumacher M; Eber B; Silberbauer K; Breier C; Stühlinger W; Schmidt P; Gaul G; Klein W
    Acta Med Austriaca; 1992; 19(5):140-4. PubMed ID: 1298143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia.
    Kehely A; MacMahon M; Barbir M; Wray R; Hunt BJ; Prescott RJ; Thompson GR
    QJM; 1995 Jun; 88(6):421-7. PubMed ID: 7648234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) cohort.
    Clearfield MB; Weis SE; Willis JM; Vasenius KA; McConathy WJ
    J Am Osteopath Assoc; 2002 Jul; 102(7):377-84. PubMed ID: 12138952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial.
    Goldenberg I; Benderly M; Goldbourt U;
    J Am Coll Cardiol; 2008 Jan; 51(4):459-65. PubMed ID: 18222357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of restenosis by bezafibrate after successful coronary angioplasty.
    Ishiwata S; Nakanishi S; Nishiyama S; Seki A
    Coron Artery Dis; 1995 Nov; 6(11):883-9. PubMed ID: 8696533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study).
    Brodov Y; Behar S; Boyko V; Chouraqui P
    Am J Cardiol; 2010 Dec; 106(12):1717-20. PubMed ID: 21126615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
    Cortellaro M; Cofrancesco E; Boschetti C; Cortellaro F; Mancini M; Mariani M; Paoletti R
    Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
    Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C;
    Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of bezafibrate in isolated hypercholesterolemia and mixed hyperlipidemia on infarct risk (Stepwise Program for Individual Risk Identification and Therapy): an open multicenter study].
    Sinzinger H; Virgolini I; Kudlacek P
    Wien Klin Wochenschr; 1991; 103(13):381-7. PubMed ID: 1897230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of bezafibrate in the diet of hypertensive patients with dyslipidemia and hyperfibrinogenemia].
    Vázquez-Chávez C; Salinas-Orozco S; Gómez-Díaz RA; Rosso-Juárez MM; Moreno-Vázquez K; Nissen-Torres T; Argüero-Sánchez R
    Rev Invest Clin; 1998; 50(6):491-6. PubMed ID: 10070221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.